Safety evaluation of piperacillin/tazobactam in very low birth weight infants

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 166-171

  Berger, A ^a,b   Kretzer, V ^a   Apfalter, P ^a   Rohrmeister, K ^a   Zaknun, D ^a   Pollak, A ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Necrotizing enterocolitis; Nosocomial infection; Piperacillin tazobactam; Preterm infant; Safety evaluation; Very low birth weight infants

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL SURGERY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL TRACT; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFANT; INTESTINE FLORA; LABORATORY TEST; LOW BIRTH WEIGHT; MALE; NECROTIZING ENTEROCOLITIS; PHLEBITIS; RASH; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SURGICAL INFECTION; TREATMENT OUTCOME;

EID: 2942569603     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.166     Document Type: Article

References (15)

1. Stoll BJ, Gordon T, Korones SB et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal research Network. J Pediatr 1996; 129: 63-71.
2. Khadilkar V, Tudehope D, Fraser S. A prospective study of nosocomial infection in a neonatal intensive care unit. J Paediatr Child Health 1995; 31: 387-391.
3. Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL. Necrotizing enterocolitis in very low birth weight infants: biodemographic and clinical correlates. J Pediatr 1991; 119: 630-8.
4. De Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-8.
5. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999; 281: 67-71.
6. Struelens MJ, Byl B, Vincent JL. Antibiotic policy: a tool for controlling resistance of hospital pathogens. Clin Microbiol Infect 1999; 5: S19-S24.
7. Hebra A, Ross AJ. Necrotizing enterocolitis. In: Spitzer AR, ed. Intensive care of the fetus and neonate. 1st ed. St. Louis: Mosby. 1996: 865-874.
8. Sanders WE, Sanders CC. Piperacillin/Tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996; 22: 107-123.
9. Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP. Safety profile of piperacillin/tazobactam in phase I and III clinical studies. J Antimicrob Chemother 1993; 31, Suppl. A: 113-124.
10. Arguedas A, Sifuentes-Osomio J, Loaiza C, Herrera M, Corrales JC, Mohs E. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. J Chemother 1996; 8: 130-6.
11. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella Pneumoniae infections in neonates. Am J Perinatol 1998; 15: 47-51.
12. Nürnberger W, Bönig H, Burdach S, Göbel U. Tolerability of piperacillin/ tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation. Infection 1998; 26: 65-7.
13. Bell MJ, Ternberg JL, Feigin RD et al. Neonatal necrotizing enterocolitis: therapeutic decision based upon clinical staging. Ann Surg 1978; 187: 1-7.
14. th informational supplement M100-S11. Wayne, PA, 2001.
15. Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL. Single-Dose Pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994; 38: 2817-26.